Northern Trust
IKT icon

Northern Trust’s Inhibikase Therapeutics IKT Stock Holding History

Northern Trust’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Buy
878,585
+159,785
+22% +$286K ﹤0.01% 3198
2026
Q1 		$1.21M Buy
718,800
+396,080
+123% +$703K ﹤0.01% 3246
2025
Q4 		$662K Sell
322,720
-51,616
-14% -$82.1K ﹤0.01% 3553
2025
Q3 		$606K Sell
374,336
-18,380
-5% -$31.8K ﹤0.01% 3585
2025
Q2 		$766K Buy
392,716
+328,705
+514% +$644K ﹤0.01% 3509
2025
Q1 		$140K Hold
64,011
– – ﹤0.01% 4036
2024
Q4 		$208K Buy
+64,011
New +$160K ﹤0.01% 3978
2023
Q2 		– Sell
-4,812
Closed -$19K – 4558
2023
Q1 		$19K Hold
4,812
– – ﹤0.01% 4457
2022
Q4 		$14.4K Hold
4,812
– – ﹤0.01% 4535
2022
Q3 		$26K Hold
4,812
– – ﹤0.01% 4497
2022
Q2 		$21K Hold
4,812
– – ﹤0.01% 4616
2022
Q1 		$43K Hold
4,812
– – ﹤0.01% 4562
2021
Q4 		$42K Buy
4,812
+2,193
+84% +$24.2K ﹤0.01% 4618
2021
Q3 		$30K Buy
+2,619
New +$35.4K ﹤0.01% 4590

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Northern Trust's IKT Position: Q2 2026 in Review

Northern Trust increased its Inhibikase Therapeutics (IKT) stake by 22% in Q2 2026, buying an estimated $286K and bringing the position to 878,585 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #3198.

Northern Trust first reported a position in IKT in Q3 2021 and has held it in 14 quarters since. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Northern Trust held 878,585 shares of Inhibikase Therapeutics worth $1.78M as of Q2 2026.
  • Northern Trust bought 159,785 Inhibikase Therapeutics shares in Q2 2026, an estimated $286K.
  • Inhibikase Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3198 holding.
  • Northern Trust first reported a position in Inhibikase Therapeutics in Q3 2021 and has held it in 14 quarters since.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.